Streetbeat News

Revenues

AXL

American Axle & Manufacturing Holdings (AXL) has reiterated its FY24 sales outlook, expecting sales between $6.05B-$6.35B, in line with the $6.2B estimate. The company also targets an Adjusted EBITDA of $685M-$750M and Adjusted free cash flow of $200M-$240M, assuming capital spending of 4.0%-4.5% of sales.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:07 pm

HAO

Haoxi Health Technology has signed an advertising placement service framework contract with Yiya Dental, committing to provide advertising services. Yiya Dental anticipates the total cooperation fees to be no less than $5.5 million.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:07 pm

NTRA

Natera announced the publication of its Signatera test in JCO Precision Oncology, highlighting its effectiveness in early detection of recurrence in early-stage breast cancer patients. The expanded EBLIS study, with up to 12 years of follow-up, supports Signatera's utility across all breast cancer subtypes.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:05 pm

CYRX

CryoPort (NASDAQ:CYRX) received mixed analyst ratings in the last quarter, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for CYRX has been updated to $18.4, reflecting a slight increase from the previous target. Analysts from firms like B. Riley Securities, Jefferies, UBS, Stephens & Co., and Needham have adjusted their ratings and price targets, indicating varying expectations for the company's performance. Despite facing challenges such as a revenue decline of -5.13% and below-average profitability metrics, CryoPort remains a key player in the life sciences industry's temperature-controlled supply chain solutions.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:01 pm

RNA

Avidity Biosciences (NASDAQ:RNA) has received diverse analyst ratings over the last three months, with a significant upward trend in its 12-month price target to $37.29, indicating a 62.13% increase from the previous average of $23.00. Analysts from firms like B of A Securities, Needham, Cantor Fitzgerald, and Chardan Capital have adjusted their ratings and price targets, reflecting a bullish outlook on the company. Despite this optimism, Avidity Biosciences faces challenges in revenue growth and efficiency metrics, with a notable revenue decline of -20.8% and concerns in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

ENOV

Recent analyst ratings for Enovis (NYSE:ENOV) show a mix of bullish sentiments with an updated average 12-month price target of $78.67, reflecting a 7.77% increase from the previous target. The company's financial performance indicates strong revenue growth, profitability, and efficient asset and debt management, positioning it favorably in the medical technology sector.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

CGNX

Over the last three months, Cognex (NASDAQ:CGNX) has been evaluated by 5 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target for CGNX has been raised to $47.2, reflecting an 11.72% increase from the previous target of $42.25. Analysts from firms including Needham, Baird, Citigroup, UBS, and Truist Securities have adjusted their ratings and price targets, indicating a positive outlook on the stock. Despite facing revenue challenges with a -17.86% decline over 3 months, Cognex's financial strength is evident in its net margin, ROE, ROA, and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

TDS

Telephone And Data Systems (TDS) reaffirmed its 2024 guidance, with UScellular projecting service revenues between $2.95B-$3.05B and TDS Telecom expecting total operating revenues of $1.07B-$1.10B. TDS Telecom has added 28,000 marketable fiber service addresses in Q1 and aims to reach 125,000 by 2024. Additionally, TDS and UScellular are exploring strategic alternatives for UScellular, with the review process still active.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:37 am

CBOE

Cboe Global Markets has provided its fiscal year 2024 financial guidance, anticipating organic net revenue growth of 5%-7%, with Data and Access Solutions revenue expected to grow 7%-10%. Adjusted operating expenses are projected to be $795M-$805M, with capital expenditures forecasted at $51M-$57M. The company also expects a non-operating income benefit of $37M-$43M from minority investments and an effective tax rate of 28.5%-30.5%.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:35 am

FUBO

FuboTV anticipates a 10% increase in North American subscribers for Q2, with projected revenues between $357.5M and $367.5M.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:34 am